Immucell (ICCC) Curent Deferred Tax Liability (2010 - 2014)

Immucell's (ICCC) quarterly Curent Deferred Tax Liability came in at $24688.0 in Q3 2014, up 3.95% on a QoQ basis from $23749.0 in Q2 2014.

Immucell (ICCC) Curent Deferred Tax Liability (2010 - 2014) Analysis & Trends

Immucell (ICCC) has 2 years of Curent Deferred Tax Liability data on file, last reported at $24688.0 in Q3 2014.

Quarterly Curent Deferred Tax Liability changed N/A year-over-year to $24688.0 in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $24688.0 (changed N/A YoY) and the FY2010 annual result came in at $4843.0, changed N/A from the prior year.
Curent Deferred Tax Liability advanced to $24688.0 in Q3 2014, from $23749.0 in the prior quarter.
In the past five years, Curent Deferred Tax Liability ranged from a high of $24688.0 in Q3 2014 to a low of $4843.0 in Q4 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax Liability (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Immucell	91.19 Mn	82.33 Mn	2.44 Mn	-

Download Data